Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Single-Arm Study of Zandelisib (ME-401) in Relapsed or Refractory FL or MZL
2018-002896-17Phase 2Unknown
- Sponsor
- MEI Pharma
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zandelisib in follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL), sponsored by MEI Pharma. Primary endpoint: Objective Response Rate (ORR). Status: unknown.
02
Drugs
zandelisib
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2018-002896-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002896-17.